T3D Therapeutics, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2013-01-01
- Employees
- 1
- Market Cap
- -
A Phase 2b/3 Clinical Study Evaluating T3D-959 in Mild-to-Moderate Alzheimer's Disease Subjects
Phase 2
Not yet recruiting
- Conditions
- Alzheimer's Disease
- Interventions
- Other: Placebo Comparator
- First Posted Date
- 2025-05-09
- Last Posted Date
- 2025-05-09
- Lead Sponsor
- T3D Therapeutics, Inc.
- Target Recruit Count
- 376
- Registration Number
- NCT06964230
- Locations
- 🇺🇸
T3D Therapeutics, Inc., Durham, North Carolina, United States
Clinical Study Evaluating Efficacy and Safety of T3D-959 in Mild-to-moderate AD Subjects
Phase 2
Completed
- Conditions
- Alzheimer Disease
- Interventions
- Drug: PlacebosDrug: 15mg T3D-959Drug: 30 mg T3D-959Drug: 45 mg T3D-959
- First Posted Date
- 2020-01-31
- Last Posted Date
- 2024-07-19
- Lead Sponsor
- T3D Therapeutics, Inc.
- Target Recruit Count
- 250
- Registration Number
- NCT04251182
- Locations
- 🇺🇸
T3D Therapeutics, Durham, North Carolina, United States
Feasibility Study in Subjects With Mild to Moderate Alzheimer's Disease
- First Posted Date
- 2015-09-25
- Last Posted Date
- 2018-07-30
- Lead Sponsor
- T3D Therapeutics, Inc.
- Target Recruit Count
- 36
- Registration Number
- NCT02560753
- Locations
- 🇺🇸
Miami Jewish Health Systems, Miami, Florida, United States
🇺🇸New Hope Clinical Research, Charlotte, North Carolina, United States
🇺🇸Brain Matters Research, Delray Beach, Florida, United States
© Copyright 2025. All Rights Reserved by MedPath